LONDON - Poolbeg Pharma plc (AIM:POLB) announced today that it has received formal notification from the European Patent Office of the decision to grant a patent for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome treatment, according to a press release statement.
The European patent provides protection across EPO member states for the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy-induced CRS. The patent is supported by proprietary data generated by the company.
This marks the third patent grant in this family, following IP Australia’s grant in March 2026 and Canada’s grant in May 2026. The company stated the European patent represents the most commercially significant grant to date within its cancer immunotherapy-induced CRS patent portfolio.
The clinical-stage biopharmaceutical company is currently conducting the TOPICAL trial, a single-arm, open-label trial investigating POLB 001 as a potential preventative for CRS in relapsed/refractory multiple myeloma patients receiving teclistamab, a bispecific antibody provided by Johnson and Johnson at no cost to Poolbeg. The company expects to deliver interim data from the trial later this summer.
Jeremy Skillington, Chief Executive Officer of Poolbeg Pharma, said: "This decision to grant the European patent further strengthens our IP protection for POLB 001 in cancer immunotherapy-induced CRS. Europe represents one of the most strategically important pharmaceutical markets and this grant increases the commercial value of POLB 001 to potential partners at a critical stage in the programme’s development."
The company stated it will provide updates regarding patent coverage extension in other jurisdictions in due course.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates POLB alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if POLB is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?